These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 25687818)

  • 1. Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management.
    Shuker N; van Gelder T; Hesselink DA
    Transplant Rev (Orlando); 2015 Apr; 29(2):78-84. PubMed ID: 25687818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tacrolimus Intrapatient Variability on Graft Outcomes in Adherent Renal Transplantation Patients: A Cross-Sectional Study.
    Nafar M; Keshtkari S; Ziaie S; Firouzan A; Borumandnia N; Dalili N; Poorrezagholi F; Samadian F; Samavat S
    Iran J Kidney Dis; 2024 May; 18(3):187-194. PubMed ID: 38904339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive review of the impact of tacrolimus intrapatient variability on clinical outcomes in kidney transplantation.
    Gonzales HM; McGillicuddy JW; Rohan V; Chandler JL; Nadig SN; Dubay DA; Taber DJ
    Am J Transplant; 2020 Aug; 20(8):1969-1983. PubMed ID: 32406604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrapatient Variability of Tacrolimus Exposure in Solid Organ Transplantation: A Novel Marker for Clinical Outcome.
    Kuypers DRJ
    Clin Pharmacol Ther; 2020 Feb; 107(2):347-358. PubMed ID: 31449663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrolimus intra-patient variability is not associated with chronic active antibody mediated rejection.
    Sablik KA; Clahsen-van Groningen MC; Hesselink DA; van Gelder T; Betjes MGH
    PLoS One; 2018; 13(5):e0196552. PubMed ID: 29746495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tacrolimus intra-patient variability measures and its associations with allograft clinical outcomes in kidney transplantation.
    Xie W; Fan S; Liu R; Yan W; Su C; Zheng K; Wang X; Wang Z
    Transplant Rev (Orlando); 2024 Jul; 38(3):100842. PubMed ID: 38537484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.
    Andrews LM; Li Y; De Winter BCM; Shi YY; Baan CC; Van Gelder T; Hesselink DA
    Expert Opin Drug Metab Toxicol; 2017 Dec; 13(12):1225-1236. PubMed ID: 29084469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining a threshold for tacrolimus intra-patient variability associated with late acute cellular rejection in paediatric kidney transplant recipients.
    Abu Bakar K; Mohamad NA; Hodi Z; McCulloch T; Williams A; Christian M; Key T; Kim JJ
    Pediatr Nephrol; 2019 Dec; 34(12):2557-2562. PubMed ID: 31520127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conversion from twice-daily to once-daily tacrolimus does not reduce intrapatient variability in tacrolimus exposure.
    Shuker N; Cadogan M; van Gelder T; Roodnat JI; Kho MM; Weimar W; Hesselink DA
    Ther Drug Monit; 2015 Apr; 37(2):262-9. PubMed ID: 25265255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of an LC-MS/MS method to measure tacrolimus in rat kidney and liver tissue and its application to human kidney biopsies.
    Noll BD; Coller JK; Somogyi AA; Morris RG; Russ GR; Hesselink DA; Van Gelder T; Sallustio BC
    Ther Drug Monit; 2013 Oct; 35(5):617-23. PubMed ID: 23921430
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.
    Wallemacq P; Armstrong VW; Brunet M; Haufroid V; Holt DW; Johnston A; Kuypers D; Le Meur Y; Marquet P; Oellerich M; Thervet E; Toenshoff B; Undre N; Weber LT; Westley IS; Mourad M
    Ther Drug Monit; 2009 Apr; 31(2):139-52. PubMed ID: 19177031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
    Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
    Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High intra-patient variability of tacrolimus within post-operative 1 month predicted worse 1-year outcomes in pediatric liver transplant recipients.
    Chen F; Yong JK; Shen C; Zhou T; Feng M; Wan P; Luo Y; Lin H; Qian Y; Xia Q
    Eur J Clin Pharmacol; 2024 Jul; 80(7):1017-1027. PubMed ID: 38502358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and pharmacodynamics of tacrolimus in liver transplant recipients: inside the white blood cells.
    Lemaitre F; Blanchet B; Latournerie M; Antignac M; Houssel-Debry P; Verdier MC; Dermu M; Camus C; Le Priol J; Roussel M; Zheng Y; Fillatre P; Curis E; Bellissant E; Boudjema K; Fernandez C
    Clin Biochem; 2015 Apr; 48(6):406-11. PubMed ID: 25562187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J; del Castillo D; Cabello M; Pallardó L; Grinyó JM; Fernández AM; Brunet M
    Transplantation; 2010 Apr; 89(8):994-1000. PubMed ID: 20335831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrapatient Variability in Tacrolimus Trough Levels Over 2 Years Affects Long-Term Allograft Outcomes of Kidney Transplantation.
    Park Y; Lee H; Eum SH; Kim HD; Ko EJ; Yang CW; Chung BH
    Front Immunol; 2021; 12():746013. PubMed ID: 34659243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of a liquid chromatography-mass spectrometric assay for tacrolimus in liver biopsies after hepatic transplantation: correlation with histopathologic staging of rejection.
    Capron A; Lerut J; Verbaandert C; Mathys J; Ciccarelli O; Vanbinst R; Roggen F; De Reyck C; Lemaire J; Wallemacq PE
    Ther Drug Monit; 2007 Jun; 29(3):340-8. PubMed ID: 17529892
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Etiologies and Outcomes Associated With Tacrolimus Levels Out of a Typical Range That Lead to High Variability in Kidney Transplant Recipients.
    Taber DJ; Hirsch J; Keys A; Su Z; McGillicuddy JW
    Ther Drug Monit; 2021 Jun; 43(3):401-407. PubMed ID: 33560095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Intrapatient Variability in Tacrolimus Exposure Calculated Over a Long Period Is Associated With De Novo Donor-Specific Antibody Development and/or Late Rejection in Thai Kidney Transplant Patients Receiving Concomitant CYP3A4/5 Inhibitors.
    Larpparisuth N; Pongnatcha T; Panprom P; Promraj R; Premasathian N; Vongwiwatana A
    Ther Drug Monit; 2021 Oct; 43(5):624-629. PubMed ID: 33278239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2004; 43(10):623-53. PubMed ID: 15244495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.